Mammogram
- Medical Review: Kristin Brill, MD, FACS
A mammogram is an imaging test that can detect breast cancer. This imaging approach is known as mammography, and it’s the best technique available to screen for breast cancer and lower the number of deaths from the disease.
If you’ve never had a mammogram, you may have concerns or questions about what the test is, what happens when you get a mammogram, when and how often you should get one, and what the test’s results mean. On this page, we’ll explain the most important things to know about mammograms and provide guidelines from the most trusted organizations.
What is a mammogram?
A mammogram is a low-dose x-ray test of the breasts that captures images of breast tissue. The images help doctors to assess breast changes that could be cancer.
Before 2000 or so, mammograms were printed on large sheets of black and white film. Now, digital mammograms are common. Digital mammograms can be recorded and saved as files in a computer. Radiologists can change the contrast of the digital image and zoom in to look more carefully at different parts of the breast.
Screening vs. diagnostic mammograms
You may have heard the terms screening and diagnostic used to describe mammograms. A screening mammogram refers to a mammogram for a person who does not have signs or symptoms of breast cancer.
A diagnostic mammogram is performed if you have signs or symptoms of breast cancer. A diagnostic mammogram may also be used if your doctor needs further study of something seen on a screening mammogram that doesn’t look normal. A diagnostic mammogram may require more pictures of the breast than a screening mammogram.
Who should get a screening mammogram?
Who should get a screening mammogram — and when and how often — depends on certain factors. One of those factors is your sex assigned at birth. Anyone can develop breast cancer, but breast cancer is much more common in women, or people assigned female at birth. Men, or people assigned male at birth, do not undergo regular screening mammograms. Another factor is whether a doctor has recommended you get the test.
Whether you have an average risk or a high risk of developing breast cancer is also an important factor in deciding when you should begin having, and how often you should have, screening mammograms. For screening purposes,
average risk means you:
- Do not have a personal history of breast cancer
- Do not have a strong family history of breast cancer
- Do not have a genetic mutation known to increase breast cancer risk
- Have not had chest radiation therapy before age 30
Mammography screening recommendations
Different professional organizations and groups have different recommendations for mammography in women at average risk. LBBC offers the recommendations of five of these groups here:
The American Cancer Society (ACS) | National Comprehensive Cancer Network (NCCN) | U.S. Preventive Services Task Force (USPSTF) | American College of Radiology (ACR) | The American Society of Breast Surgeons (ASBrS) | |
---|---|---|---|---|---|
Age to start screening mammograms | 45; option to begin at 40 | 40 | 40 | 40 | 40 |
How often to screen | <54, every year; >55, every other year* | Every year | Every other year | Every year | Every year |
*Every year up to and including age 54; at age 55, option to screen every year or every other year if they are in good health and are expected to live at least 10 more years
For people at average risk, here are the major similarities and differences in mammogram screening recommendations:
- Most of the organizations listed above recommend that screening begin at age 40.
- The exception: The American Cancer Society (ACS) suggests age 40 as an option and 45 as the recommendation.
- Most of the organizations recommend annual screening mammograms (every year), with ACS recommending annual screenings until at least age 54.
- The exception: The U.S. Preventive Services Task Force (USPSTF) recommends screening mammograms every other year.
There are different mammogram screening guidelines for people who are at increased risk of breast cancer. Factors that increase risk include a family history of breast cancer, inherited high-risk genetic mutations such as BRCA1 or BRCA2, and having dense breasts. Learn more about risk factors.
For women who are at increased risk of developing breast cancer:
ACS | NCCN | USPSTF | ACR | ASBrS | |
---|---|---|---|---|---|
Age to start screening mammograms | Between age 30-40* | 30, + breast MRI as early as age 25 | No specific recommendation | 25 or 30* | 30 or 35* |
How often to screen | Mammogram + breast MRI every year | Mammogram + breast MRI every year | No specific recommendation | Every year** | Every year** |
*Depending on risk factors
**Possibly adding breast MRI, depending on risk factors
Most recommendations for women at high risk for a breast cancer diagnosis include breast MRI as well as mammograms. As shown in the chart above, most of the organizations recommend annual screening mammograms starting between ages 25 and 35 for people at high risk, depending on individual risk factors. The exception is the USPSTF, which does not have specific screening recommendations for people at high risk.
Some states do not legally require health insurance companies to pay for extra screenings for people at high risk. If you are at increased risk of breast cancer and your insurance provider does not cover high-risk screenings, you can learn about options in our Paying for your mammogram section below.
With different professional groups making different and sometimes conflicting recommendations, it can be confusing and frustrating to know what kind of screening plan is best. No matter how old you are, talk with your doctor about your individual risk for breast cancer and what kind of screening plan is most appropriate for you.
Understanding your risk of breast cancer
If you are unsure about whether you are at an increased risk for breast cancer, talk to your doctor about getting a risk assessment. NCCN recommends women have a breast cancer risk assessment by age 25. The ACR recommends women, especially women who are Black or of Ashkenazi Jewish descent, have a risk assessment by age 30. Learn more about risk in Who gets breast cancer?
Two-dimensional (2D) versus three-dimensional (3D) mammograms
You may have heard the terms 2D and 3D mammogram used to describe different kinds of mammograms. Here, we’ll explain what they are and how they are different:
- 2D mammogram: A standard mammogram is two-dimensional, or 2D. With 2D mammograms, x-ray images are taken from two different angles (top to bottom and side to side).
- 3D mammogram: Three-dimensional, or 3D, mammograms take many images as the machine moves in a small arc around the breast. A computer puts these images together, allowing doctors to view the mammography from multiple angles. 3D mammograms are also known as digital tomosynthesis. Many centers offer 3D mammograms, which may allow doctors to see images of breast tissue more clearly.
Some systems automatically apply both 2D and 3D mammography as part of the screening.
Preparing for your mammogram
There are a few ways to prepare for a mammogram. In this section, we’ll take you through each step.
Scheduling your mammogram
Mammograms are usually performed at outpatient imaging centers or breast centers that are part of a hospital or health system. To schedule a mammogram, call the hospital’s main phone number, scheduling department number, or women’s health or breast center and ask to be connected with someone who can schedule a mammogram.
How quickly a center can get you scheduled for a mammogram depends on the facility and whether you ask for a screening or diagnostic mammogram. If you are concerned that you need to be scheduled sooner than what is offered to you, ask your doctor for assistance.
How to prepare on the day of the mammogram
On the day of the test, it is best not to wear deodorant, antiperspirant, creams, lotions, or perfumes under your arms or on or under your breasts. Sometimes these types of products show up as white spots on x-rays, which could make it harder for the radiologist to read.
If you are premenopausal or perimenopausal, you may want to consider not scheduling a mammogram the week before your period or during your period if possible, because breast tissue can be tender at that time and a mammogram may feel painful.
Otherwise, you do not need to change any normal activities such as exercise, drinking alcohol, or any other parts of your lifestyle before having a mammogram.
What to expect during your mammogram
Before the test, you will be asked to fill out a breast health history questionnaire. You will then be taken to a dressing room to remove your shirt and bra and put on a gown. You will probably need to wait in a waiting room for a few minutes before a technologist takes you to the mammography room.
The technologist will help you remove part of your gown and place each breast, one at a time, on the mammogram machine. Two plates will compress or flatten each breast while a camera attached to the plates takes pictures from different angles. Flattening the tissue gives radiologists — doctors who specialize in using imaging technology to diagnose disease — a better quality image that also uses less radiation than other kinds of x-rays.
It’s normal to be concerned about pain or discomfort while the plates compress your breasts and the camera takes pictures. Some people have some pain, but it usually goes away quickly after the compression, which lasts about 10 to 15 seconds. If you are about to have your period and your breasts are tender, you may have more discomfort than you would at other times of the month. The actual mammogram takes about 10 to 15 minutes.
Paying for your mammogram
Getting the cost of a mammogram covered can be different in different situations, especially if you have a high risk for breast cancer. But there are ways to find help if you have difficulty.
If you are at average risk
Most health insurance companies, under the Affordable Care Act, must cover screening mammograms at no cost for women at average risk who are ages 40 to 50, once a year or once every 2 years.
Many states require Medicaid and public employee health plans to cover screening mammograms. For Medicare beneficiaries aged 40 and older, Medicare pays for yearly screening mammograms and for one baseline mammogram for women ages 35 to 39.
If you are uninsured or underinsured, there are resources to help you get a mammogram at no cost to you. The Centers for Disease Control and Prevention’s National Breast and Cervical Cancer Early Detection Program helps women in each state find programs that will help them get screening and diagnostic mammograms at no cost to them.
People who do not have insurance who pay out of pocket for a mammogram can expect to pay $65 to $380 for a screening mammogram and $150 to $1046 for a diagnostic mammogram.
If you are at high risk
Depending on the laws in your state, if you have a high risk of developing breast cancer, your insurance plan may not cover extra mammogram screenings. If this is your situation, ask your healthcare team for guidance. Sometimes, they can work with your insurance company to help you get coverage or point you to financial assistance resources.
Even if your state does not have laws in place requiring insurance companies to cover high-risk screening, many state legislators have introduced bills to require coverage. There is also a federal bill called the Find it Early Act that was recently introduced to Congress. If passed, the bill would ensure that people at high risk can get the screenings they need at no cost. You can learn more about high-risk coverage laws in your state at DenseBreast-info.org.
If you have concerns about paying for breast cancer screening tests, visit LBBC’s Financial matters section and Financial assistance page.
Mammogram results
After a screening mammogram, the speed of receiving results can vary depending on the mammography center. Some centers deliver results before you leave your mammogram appointment. With other centers, you may receive results within 2 to 4 weeks. For a diagnostic mammogram, you can expect to receive your results more quickly. Whether you are having a screening or diagnostic mammogram, you may want to ask the mammography technologist how long you can expect to wait for results.
In some cases, a person may get “called back” for additional imaging after getting a screening mammogram. A recommendation for additional imaging does not mean you have breast cancer. It means the doctors have seen something they want to look at more closely. At LBBC, we know that being called back can trigger fear and anxiety. But most women who get called back for more imaging are not found to have breast cancer.
It’s also important to know that a mammogram alone rarely gives enough information to diagnose breast cancer. If your doctor suspects cancer, you are likely to need other tests to confirm the diagnosis.
How mammogram results are interpreted
A mammogram could find a number of different breast changes, many of which are not cancer. The radiologist will look for:
- Asymmetries that look white on a mammogram
- Areas where breast tissue looks distorted or pulled toward a certain point
- Masses, or areas of abnormal breast tissue, including cysts (non-cancerous, fluid-filled sacs) or fibroadenomas (solid masses that may or may not be cancer)
- Thickening of the skin
- Calcifications (deposits or tiny specks of calcium), which are usually harmless but could be a sign of cancer
- Breast density, a measure of fibrous and glandular tissue as compared to fat tissue in the breast
If your results say you have dense breasts
In some cases, the results report may say that dense breast tissue was found. Dense breasts have more fibrous and glandular tissue than fat tissue. About half of women aged 40 and older have dense breast tissue. Dense breast tissue can make it harder to see cancer because it appears white on a mammogram, and cancer does too. Dense breasts also raise the risk of breast cancer. But talking with your doctor about a high-risk screening plan can help manage that risk.
What to do if you get an abnormal reading
If a radiologist sees one of the findings outlined above or anything that looks abnormal, it doesn’t necessarily mean a cancer diagnosis. The radiologist may recommend additional tests, such as an ultrasound or MRI.
In some cases, the radiologist may also recommend a biopsy. A biopsy is a procedure that removes a sample of tissue. The sample is sent to a lab where a pathologist will examine it under a microscope. If the biopsy results are negative or benign, no cancer was found. If cancer is found, your doctor or nurse will refer you to a breast cancer oncologist or breast surgeon to figure out next steps.
Breast Imaging Reporting and Data System (BI-RADS)
Radiologists use a standard system called Breast Imaging Reporting and Data System (BI-RADS) to describe mammogram findings and results. It uses a numbered system of 0 through 6 that the radiologist who reads your mammogram will use to categorize your results.
Here are the BI-RADS categories:
- BI-RADS 0 means additional testing is needed
- BI-RADS 1 means the result is negative or normal
- BI-RADS 2 means a benign (non-cancerous) finding
- BI-RADS 3 means a probable benign finding and follow-up is suggested
- BI-RADS 4 means there is a suspicious abnormality and biopsy should be considered
- BI-RADS 5 means the finding is highly suggestive of cancer and biopsy is strongly recommended
- BI-RADS 6 means that the biopsy has confirmed cancer; this BI-RADS category is used with mammogram or other diagnostic imaging that is performed after a biopsy
Mammogram accuracy
Mammograms are the best breast cancer screening tests available, but they are not 100% accurate in diagnosing breast cancer. They miss 1 in 8 breast cancers. If you are concerned about the accuracy of your mammogram, talk with your healthcare team about your individual risk of breast cancer and whether they may recommend additional imaging techniques.
Mammogram risks
While mammograms expose the breasts to a small amount of radiation, the benefits of early detection outweigh the risks of radiation exposure.
Mammogram FAQs
Here are answers to some of the most common questions about mammograms.
Do mammograms hurt?
You may have brief discomfort or pain during the 10 to 15 seconds when your breast is compressed between the machine’s plates, especially if you get the test right before or during your period.
How often should I get a mammogram?
Most professional organizations recommend getting a screening mammogram every year. Some groups recommend getting a screening mammogram every other year. Talk with your doctor about what is the best choice for you.
At what age should I start getting mammograms?
If you are at average risk for breast cancer, most professional organizations recommend you start getting a screening mammogram at age 40. If you are at high risk, some organizations recommend you start at age 25 or 35. It’s best to talk to your doctor about what age is right for you, depending on your risk factors.
Does a mammogram show under my armpit?
While mammograms may be able to see some parts of your underarm, they may not always be able to view all of it. Breast cancer cells can sometimes travel to lymph nodes — small immune system organs — in the armpit area. The most accurate way to tell if cancer is in lymph nodes is through sentinel lymph node biopsy or axillary lymph node dissection surgery. You can learn more on the lymph node surgery page.
Do mammograms have negative side effects?
Mammograms expose the breasts to very small amounts of radiation, but the benefits of getting a mammogram outweigh any harm.
Related news
- Living Beyond Breast Cancer and LUNGevity Foundation Expand the No One Missed Campaign to the Breast Cancer Community
- Beyond the headlines: Survival, breast screening, scans in metastatic breast cancer
- Beyond the headlines: USPSTF screening guidelines, disparities, and mental health
- Beyond the headlines: March 2023
Related downloads
View allStay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer
- radiosurgery
- radiotherapy
- raloxifene
- raloxifene hydrochloride
- randomization
- randomized clinical trial
- receptor
- RECIST
- reconstructive surgeon
- reconstructive surgery
- recreational therapy
- recurrence
- recurrent cancer
- referral
- reflexology
- refractory
- refractory cancer
- regimen
- regional
- regional anesthesia
- regional cancer
- regional chemotherapy
- regional lymph node
- regional lymph node dissection
- registered dietician
- regression
- rehabilitation
- rehabilitation specialist
- relapse
- relative survival rate
- relaxation technique
- remission
- remission induction therapy
- remote brachytherapy
- research nurse
- research study
- resectable
- resected
- resection
- residual disease
- resistant cancer
- resorption
- respite care
- response rate
- retrospective cohort study
- retrospective study
- risk factor
- Rubex
- salpingo-oophorectomy
- salvage therapy
- samarium 153
- sargramostim
- scalpel
- scan
- scanner
- scintigraphy
- scintimammography
- sclerosing adenosis
- screening
- screening mammogram
- second-line therapy
- second-look surgery
- second primary cancer
- secondary cancer
- secrete
- sedative
- segmental mastectomy
- selection bias
- selective estrogen receptor modulator
- selective serotonin reuptake inhibitor
- sentinel lymph node
- sentinel lymph node biopsy
- sentinel lymph node mapping
- sepsis
- sequential AC/Taxol-Trastuzumab regimen
- sequential treatment
- SERM
- sertraline
- Serzone
- sestamibi breast imaging
- sexuality
- sibling
- side effect
- silicone
- simple mastectomy
- simulation
- Single-agent therapy
- sleep disorder
- social service
- social support
- social worker
- sodium thiosulfate
- soft tissue
- solid tumor
- somatic
- somatic mutation
- sorafenib
- specialist
- specificity
- spiculated mass
- spinal anesthesia
- spinal block
- spiral CT scan
- spirituality
- sporadic cancer
- SSRI
- stable disease
- stage
- stage 0 breast carcinoma in situ
- stage 0 disease
- stage I breast cancer
- stage IA breast cancer
- stage IB breast cancer
- stage II breast cancer
- stage II breast cancer
- stage IIA breast cancer
- stage IIB breast cancer
- stage III breast cancer
- stage III lymphedema
- stage IIIA breast cancer
- stage IIIB breast cancer
- stage IIIC breast cancer
- stage IV breast cancer
- staging
- stamina
- standard of care
- standard therapy
- statistically significant
- stent
- stereotactic biopsy
- stereotactic radiosurgery
- sterile
- sternum
- steroid
- stress
- strontium
- study agent
- subcutaneous
- subcutaneous port
- subjective improvement
- subset analysis
- supplemental nutrition
- supplementation
- support group
- supportive care
- supraclavicular lymph node
- surgeon
- surgery
- surgical biopsy
- surgical menopause
- surgical oncologist
- survival rate
- symptom
- symptom management
- symptomatic
- synergistic
- synthetic
- syringe
- systemic
- systemic chemotherapy
- systemic disease
- systemic therapy
- TAC regimen
- tai chi
- tailored intervention
- talk therapy
- tamoxifen
- targeted therapy
- taxane
- Taxol
- Taxotere
- Tc 99m sulfur colloid
- technician
- terminal disease
- therapeutic
- therapeutic touch
- therapy
- thermography
- thiethylperazine
- thiotepa
- third-line therapy
- thrush
- time to progression
- tinnitus
- tissue
- tissue flap reconstruction
- TNM staging system
- tomography
- tomotherapy
- topical
- topical chemotherapy
- topoisomerase inhibitor
- total estrogen blockade
- total mastectomy
- total nodal irradiation
- total parenteral nutrition
- toxic
- toxicity
- tracer
- traditional acupuncture
- tranquilizer
- transdermal
- transfusion
- transitional care
- translational research
- trastuzumab
- trauma
- treatment field
- trigger
- trigger point acupuncture
- triple-negative breast cancer
- tumescent mastectomy
- tumor
- tumor antigen vaccine
- tumor board review
- tumor burden
- tumor debulking
- tumor load
- tumor marker
- tumor volume
- Tykerb
- ulcer
- ulceration
- ultrasound-guided biopsy
- ultrasound/ultrasonography
- ultraviolet radiation therapy
- uncontrolled study
- undifferentiated
- unilateral
- unilateral salpingo-oophorectomy
- unresectable
- unresected
- upstaging
- urticaria
- VACB
- vaccine therapy
- vacuum-assisted biopsy or vacuum-assisted core biopsy
- Valium
- vancomycin
- vandetanib
- vascular endothelial growth factor-antisense oligonucleotide
- vascular endothelial growth factor receptor tyrosine kinase inhibitor
- vein
- Velban
- venipuncture
- venous sampling
- Versed
- vertebroplasty
- vinorelbine
- vital
- vomit
- watchful waiting
- wedge resection
- Wellcovorin
- Western medicine
- WGA study
- white blood cell
- whole cell vaccine
- whole genome association study
- wide local excision
- wire localization
- wound
- X-ray therapy
- Xanax
- Xeloda
- xerostomia
- Xgeva
- yoga
- ziconotide
- Zinecard
- Zofran
- zoledronic acid
- Zoloft
- Zometa
Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.